[Comparative efficacy of diclobrou for prophylaxis of NSAID-associated gastropathies in patients with osteoarthritis].

As may as 155 patients with exacerbated osteoarthrosis were examined to compare the incidence of development of erosive-and-ulcerous lesions in the gastroduodenal system under exposure to different schemes of nonsteroid-antiinflammatory drug (NAID)-therapy and over different time ranges of its administration and to assess prophylactic efficacy of the drug diclobrou (enterosoluble form of diclofenac natrium). There has been endoscopically validated usefulness of employing enterosoluble and injectable dosage forms during the first days of NAID-therapy. With signs of synovitis still in place, subsequent therapy treatments are to be administered with selective inhibitors of cyclooxigenase-2 or a simple dosage form of diclofenac should be combined with misoprostol.